Answers are grounded in this paper and cite their sources.
ABI-007 demonstrated greater efficacy and a favorable safety profile compared with standard paclitaxel in this patient population. The improved therapeutic index and elimination of corticosteroid premedication required for solvent-based taxanes make the novel albumin-bound paclitaxel ABI-007 an important advance in the treatment of MBC.
No takes yet. Share an insight, caveat, or question.
Gradishar et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: